Onzima Ventures PLC Update on Investment
06 Setembro 2016 - 6:38AM
UK Regulatory
TIDMONZ
Onzima Ventures PLC
("Onzima" or the "Company")
Investee company N4 Pharma announces formation of scientific advisory panel
N4 Pharma Limited ("N4 Pharma"), in which Onzima holds a 49% equity stake, has
announced that its intellectual property partner OPAL IP has formed a
scientific advisory panel to provide advice and guidance on N4 Pharma's
reformulation projects, the first of which is its reformulation of sildenafil.
The panel is made up of Professor Karrar Khan, formerly Head of Pharmaceutical
Development for Boots Pharmaceuticals and Knoll, Doctor David Templeton, an
expert in pharmacokinetics and translational science, and Doctor Sean
McCrossen, an expert in pharmaceutical development.
N4 Pharma CEO Nigel Theobald commented:
"This is a very strong advisory panel which together brings over 90 years'
experience to our development programs. It will be a huge asset to help make
sure that our reformulations meet the requirements of industry and the
regulators and we are delighted that OPAL IP has been able to put together such
a strong team."
For further information please contact:
Onzima Ventures PLC Tel: +44
(0) 1732 366 561
Gavin Burnell, Luke Cairns
Nominated Adviser
Cairn Financial Advisers LLP Tel: +44
(0) 20 7148 7900
Sandy Jamieson, Liam Murray
Broker
Peterhouse Corporate Finance Limited Tel: +44 (0) 20
7469 0930
Guy Miller, Lucy Williams
END
(END) Dow Jones Newswires
September 06, 2016 05:38 ET (09:38 GMT)
Onzima Ventures (LSE:ONZ)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Onzima Ventures (LSE:ONZ)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024
Notícias em tempo-real sobre Onzima Ventures da Bolsa de Valores de Londres bolsa de valores: 0 artigos recentes
Mais Notícias de Onzima Ventures